Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 39.50 | -0.44% |
| CAC 40 | 7,811.26 | 110.42 | -1.39% |
| DAX 40 | 25,371.75 | 273.29 | -1.07% |
| Dow JONES (US) | 52,773.39 | 82.70 | -0.16% |
| FTSE 100 | 10,725.03 | 27.85 | -0.26% |
| HKSE | 22,934.68 | 717.19 | -3.03% |
| NASDAQ | 25,938.03 | 764.82 | -2.86% |
| Nikkei 225 | 62,907.84 | 1,713.40 | -2.65% |
| NZX 50 Index | 13,746.84 | 14.45 | -0.11% |
| S&P 500 | 7,644.87 | 112.30 | -1.45% |
| S&P/ASX 200 | 8,793.20 | 38.10 | -0.43% |
| SSE Composite Index | 3,658.03 | 55.00 | -1.48% |